Conference Coverage

AAN: Study supports safety of fingolimod for MS

Publish date: May 6, 2015

 

AT THE AAN 2015 ANNUAL MEETING

References

Dr. Cohen disclosed ties with Novartis, which funded the study.

emechcatie@frontlinemedcom.com

Pages

Recommended Reading

FDA issues new pregnancy/lactation drug label standards
MDedge Internal Medicine
Rx for specialists: Know how ACA affects patients’ ability to pay for meds
MDedge Internal Medicine
Switch to oral fingolimod produces better MS outcomes
MDedge Internal Medicine
‘No evidence of disease activity’ has potential as a useful outcome in MS
MDedge Internal Medicine
New patient registry aims to become ‘Framingham’ of MS
MDedge Internal Medicine
DMT may reduce disability-worsening events in multiple sclerosis
MDedge Internal Medicine
Interferon beta, glatiramer acetate prove effective for relapsing MS
MDedge Internal Medicine
FDA approves first generic version of MS drug glatiramer acetate
MDedge Internal Medicine
DECIDE: Daclizumab cuts MS relapse rate by 45%
MDedge Internal Medicine
Peginterferon beta-1a MS data show positive early and long-term results
MDedge Internal Medicine